A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, Li-Tzong | - |
dc.contributor.author | Satoh, Taroh | - |
dc.contributor.author | Ryu, Min-Hee | - |
dc.contributor.author | Chao, Yee | - |
dc.contributor.author | Kato, Ken | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Chen, Jen-Shi | - |
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Yeh, Kun-Huei | - |
dc.contributor.author | Yoshikawa, Takaki | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Bai, Li-Yuan | - |
dc.contributor.author | Tamura, Takao | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Hamamoto, Yasuo | - |
dc.contributor.author | Kim, Jong Gwang | - |
dc.contributor.author | Chin, Keisho | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Minashi, Keiko | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Tsuda, Masahiro | - |
dc.contributor.author | Sameshima, Hiroki | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.contributor.author | Boku, Narikazu | - |
dc.date.accessioned | 2021-08-31T01:03:39Z | - |
dc.date.available | 2021-08-31T01:03:39Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/56066 | - |
dc.description.abstract | Background Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with >= 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein. Methods ATTRACTION-2 was a randomized, double-blind, placebo-controlled, phase 3 trial (49 sites; Japan, South Korea, and Taiwan). The median (min-max) follow-up period was 27.3 (24.1-36.3) months. The primary endpoint was OS. A subanalysis of OS was performed based on best overall response and tumor-programmed death ligand-1 (PD-L1) expression status. Results Overall, 493 of 601 screened patients were randomized (2:1) to receive nivolumab (330) or placebo (163). OS (median [95% confidence interval; CI]) was significantly longer in the nivolumab group (5.26 [4.60-6.37] vs 4.14 [3.42-4.86] months in placebo group) at the 2-year follow-up (hazard ratio [95% CI], 0.62 [0.51-0.76]; P < 0.0001). A higher OS rate was observed in the nivolumab vs placebo group at 1 (27.3% vs 11.6%) and 2 years (10.6% vs 3.2%). The OS benefit was observed regardless of tumor PD-L1 expression. Among patients with a complete or partial response (CR or PR) in the nivolumab group, the median OS (95% CI) was 26.6 (21.65-not applicable) months; the OS rates at 1 and 2 years were 87.1% and 61.3%, respectively. No new safety signals were identified. Conclusions Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer. The long-term survival benefit of nivolumab was most evident in patients with a CR or PR. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | SQUAMOUS-CELL CARCINOMA | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | DOCETAXEL | - |
dc.subject | EFFICACY | - |
dc.subject | MELANOMA | - |
dc.subject | SAFETY | - |
dc.subject | TRIAL | - |
dc.subject | HEAD | - |
dc.title | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.1007/s10120-019-01034-7 | - |
dc.identifier.scopusid | 2-s2.0-85077072708 | - |
dc.identifier.wosid | 000503658700001 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, v.23, no.3, pp.510 - 519 | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.citation.title | GASTRIC CANCER | - |
dc.citation.volume | 23 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 510 | - |
dc.citation.endPage | 519 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | HEAD | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Gastroesophageal junction cancer | - |
dc.subject.keywordAuthor | Long-term | - |
dc.subject.keywordAuthor | Nivolumab | - |
dc.subject.keywordAuthor | Placebo | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.